- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06840886
Badanie Phst001 w zaawansowanych guzach litych
Badanie eskalacji i ekspansji dawki, fazy 1A/1B, badanie bezpieczeństwa, farmakokinetyki, farmakodynamiki i aktywności przeciwnowotworowej PHST001 u dorosłych pacjentów z zaawansowanymi nawrotowymi i/lub ogniotrwałymi nowotworami stałymi
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.
The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
Przegląd badań
Status
Warunki
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Raphaël Rousseau, Chief Medical Officer, PhD, MD
- Numer telefonu: 650-260-8443
- E-mail: medical@pheast.com
Lokalizacje studiów
-
-
California
-
Beverly Hills, California, Stany Zjednoczone, 90212
- Rekrutacyjny
- Precision NextGen Oncology & Research Center
-
Kontakt:
- Jing Liu
- Numer telefonu: 424-777-0708
- E-mail: JingL@nextgenonc.com, research@nextgenonc.com
-
Główny śledczy:
- Kamlesh Kumar Sankhala, MD
-
Los Angeles, California, Stany Zjednoczone, 90033
- Rekrutacyjny
- USC Norris Comprehensive Cancer Center
-
Kontakt:
- Lorraine Martinez
- E-mail: Lorraine.Martinez@med.usc.edu
-
Kontakt:
- Stephanie Kim
- E-mail: Stephanie.Kim2@med.usc.edu
-
Palo Alto, California, Stany Zjednoczone, 94304
- Rekrutacyjny
- Stanford University School of Medicine
-
Kontakt:
- Kayla McDaniel
- Numer telefonu: 650-498-7293
- E-mail: mcda59@stanford.edu
-
Główny śledczy:
- Oliver Dorigo, MD, PhD
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rekrutacyjny
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
-
Kontakt:
- Sarah Cannon Research Institute at HCA HealthONE
- Numer telefonu: 720-754-2610
- E-mail: CANN.DDUDenverGeneral@SarahCannon.com
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06520
- Rekrutacyjny
- Yale Cancer Center
-
Główny śledczy:
- Michael Cecchini, MD
-
Kontakt:
- Priscilla Stéve
- Numer telefonu: 203-464-5564
- E-mail: Priscilla.steve@yale.edu
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Rekrutacyjny
- Dana Farber Cancer Institute
-
Główny śledczy:
- Michael Dennis, MD
-
Kontakt:
- DFCI CCTI Referrals
- E-mail: dfcicctiexternalreferral@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- University of Michigan Rogel Cancer Center
-
Główny śledczy:
- Ulka Vaishampayan, MD
-
Kontakt:
- University of Michigan Health Cancer AnswerLine
- Numer telefonu: 1-800-865-1125
- E-mail: canceranswerline@med.umich.edu
-
Grand Rapids, Michigan, Stany Zjednoczone, 49546
- Rekrutacyjny
- START Center for Cancer Research - Midwest
-
Główny śledczy:
- Sreenivasa Chandana, MD, PhD
-
Kontakt:
- START HOPE Team
- E-mail: hopeteam@startresearch.com
-
-
New York
-
Lake Success, New York, Stany Zjednoczone, 11042
- Rekrutacyjny
- START Center for Cancer Research - Long Island New York
-
Główny śledczy:
- Geraldine O'Sullivan Coyne, MD
-
Kontakt:
- Sadia Morium
- Numer telefonu: 363-207-5166
- E-mail: sadia.morium@startresearch.com
-
New York, New York, Stany Zjednoczone, 10029
- Rekrutacyjny
- Mount Sinai
-
Główny śledczy:
- Thomas Marron, MD, PhD
-
Kontakt:
- Jordan Cuevas
- Numer telefonu: 212-824-7945
- E-mail: jordan.cuevas@mssm.edu
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Rekrutacyjny
- Duke Cancer Institute
-
Kontakt:
- Phase 1 and Immunotherapy Team
- Numer telefonu: 919-684-6342
- E-mail: Phase1andImmunotherapyreferrals@duke.edu
-
Główny śledczy:
- Niharika Mettu, MD, PhD
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- Vanderbilt-Ingram Cancer Center
-
Kontakt:
- Clinical Trials Office (CTO)
- Numer telefonu: 1-800-811-8480
- E-mail: cip@vumc.org
-
Główny śledczy:
- Elizabeth Davis, MD, PhD
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- Sarah Cannon Research Institute (SCRI) Oncology Partners
-
Główny śledczy:
- Deepak Bhamidipati, MD
-
Kontakt:
- SCRI Oncology Partners - Nashville
- Numer telefonu: 1-877-MY-1-SCRI (691-7274)
- E-mail: ASKSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Rekrutacyjny
- START Center for Cancer Research - Texas
-
Kontakt:
- START HOPE Team
- E-mail: hopeteam@startresearch.com
-
Główny śledczy:
- Henry Xiong, MD, PhD
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- MD Anderson Cancer Center
-
Kontakt:
- MD Anderson Cancer Center
- Numer telefonu: 713-563-1930
- E-mail: ICTNPCS@mdanderson.org
-
Główny śledczy:
- Stéphane Champiat, MD, PhD
-
Irving, Texas, Stany Zjednoczone, 75039
- Rekrutacyjny
- NEXT Oncology - Dallas
-
Główny śledczy:
- Michael Song, MD, PhD, PharmD
-
Kontakt:
- NEXT Referrals-Dallas
- Numer telefonu: fax: 210-568-4577
- E-mail: nxt_txreferrals@nextoncology.com
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Rekrutacyjny
- University of Texas (UT) Health
-
Główny śledczy:
- Daruka Mahadevan, MD, PhD
-
Kontakt:
- Mays Cancer Center Research Team
- E-mail: mccresearch@uthscsa.edu
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Rekrutacyjny
- START Center for Cancer Research - San Antonio
-
Główny śledczy:
- Kyriakos Papadopoulos, MD
-
Kontakt:
- START HOPE Team
- Numer telefonu: 210-593-5250
- E-mail: hopeteam@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Rekrutacyjny
- NEXT Oncology - Virginia
-
Kontakt:
- Carrie Friedman
- E-mail: adelgado@nextoncology.com
-
Kontakt:
- Allison Delgado
- E-mail: carrie.friedman@usoncology.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Key Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
- Adequate organ function per laboratory testing
- Pregnancy prevention requirements
- Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
Key Exclusion Criteria:
- Diagnosis of immunodeficiency
- History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
- Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
- Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
- Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
- Received previous treatment with another agent targeting CD24.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: PHST001 Monotherapy
Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. |
|
Eksperymentalny: PHST001 + Paclitaxel
Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Paclitaxel used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + Topotecan
Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Topotecan used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + Doxorubicin
Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Doxorubicin used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + FOLFIRI
Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFIRI used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + FOLFOX
Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFOX used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + Gemcitabine
Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Gemcitabine used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + Mirvetuximab Soravtansine
Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Mirvetuximab soravtansine used as per standard of care.
Inne nazwy:
|
|
Eksperymentalny: PHST001 + Trastuzumab Deruxtecan
Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Trastuzumab deruxtecan used as per standard of care.
Inne nazwy:
|
|
Aktywny komparator: Mirvetuximab Soravtansine Monotherapy
Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy. |
Mirvetuximab soravtansine used as per standard of care.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From first dose of PHST001 through 21 days after the first dose of PHST001
|
Based on toxicities observed |
From first dose of PHST001 through 21 days after the first dose of PHST001
|
|
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From signed consent up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From signed consent up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression. |
From screening and during treatment up to 2 years
|
|
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
|
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
Ramy czasowe: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to the date of death. |
From screening and during treatment up to 2 years
|
|
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as the maximum blood concentration of a dose of PHST001 |
From treatment until 90 days after last dose of PHST001
|
|
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration. |
From treatment until 90 days after last dose of PHST001
|
|
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration). |
From treatment until 90 days after last dose of PHST001
|
|
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile. |
From treatment until 90 days after last dose of PHST001
|
|
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered. |
From treatment until 90 days after last dose of PHST001
|
|
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream. |
From treatment until 90 days after last dose of PHST001
|
|
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Ramy czasowe: From treatment until 90 days after last dose of PHST001
|
Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination. |
From treatment until 90 days after last dose of PHST001
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Choroby Układu Nerwowego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Nowotwory według typu histologicznego
- Choroby macicy
- Choroby narządów płciowych, kobiety
- Nowotwory gruczołów dokrewnych
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Choroby jajników
- Choroby przydatków
- Nowotwory narządów płciowych, kobiety
- Zaburzenia gonad
- Choroby skórne
- Choroby piersi
- Rak
- Nowotwory Układu Nerwowego
- Nowotwory macicy
- Mięsak
- Nowotwory, tkanka łączna i miękka
- Nowotwory złożone i mieszane
- Choroby jajowodów
- Choroby skóry i tkanki łącznej
- Nowotwory jajnika
- Nowotwory piersi
- Rak dróg żółciowych
- Nowotwory endometrium
- Mięsak rakowy
- Nowotwory ośrodkowego układu nerwowego
- Nowotwory jajowodu
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Związki heterocykliczne, 2-ring
- Związki heterocykliczne, sterowanie stopieniem
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Węglowodany
- Campptothecin
- Alkaloidy
- Policykliczne aromatyczne węglowodory
- Węglowodory, aromatyczne
- Związki policykliczne
- Glikozydy
- Enzymy i koenzymy
- Taksoidy
- Cyklodekan
- Diterpenes
- Deoksycytydyna
- Cytydyna
- Nukleozydy pirymidynowe
- Pirymidyn
- FormylTetrahydrofolates
- Tetrahydrofolety
- Kwas foliowy
- Pterins
- Perydyny
- Uracyl
- Pirymidynony
- Antracykliny
- Naftaceny
- Aminoglikozydy
- Koenzymy
- Daunorubicyna
- Gemcytabina
- Fluorouracyl
- Leukoworyna
- Doksorubicyna
- Paklitaksel
- Topotekan
- mirvetuximab soravtansyn
- trastuzumab deruxtecan
- Protokół folfox
- Protokół IFL
Inne numery identyfikacyjne badania
- PHST001-101
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .